Aurobindo given FDA OK for generic DDAVP
Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus, and for the management of primary nocturnal enuresis.
Aurobindo has received permission from the Food and Drug Administration for desmopressin acetate tablets, 0.1mg and 0.2 mg, which are the generic of Ferring’s DDAVP.
Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus, and for the management of primary nocturnal enuresis.
[Read more: Aurobindo given FDA approval for Isotretinoin Capsules]
Desmopressin acetate tablets have an estimated market value of $28 million for the 12 months ending January 2024, per IQVIA.